Tencent returned to help the AI drug discovery platform hike its overall funding to $174m with a round that will support hiring and technology development.
US-based drug discovery technology provider Atomwise completed a $123m series B round yesterday that included internet group Tencent and two undisclosed insurance firms.
Venture capital firm B Capital Group and the Saudi state-owned Sanabil Investments co-led the round, which also featured DCVC (also known as Data Collective), Y Combinator, Dolby Family Ventures, AME Cloud Ventures and BV.
Atomwise has created a system called AtomNet that utilises artificial intelligence to help researchers design and develop therapeutic treatments for disease targets previously…
